FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

HALT-MS: Stem Cell Transplant Durable at 5 Years in MS































Image Source: ESMAS

Most recent data from a small, phase 2 study of autologous hematopoietic cell transplantation for multiple sclerosis shows that two-thirds of the patients had a sustained remission of disease 5 years after transplant.

Sixty-nine percent of patients met the primary endpoint of event-free survival.

"That's certainly much higher than any other treatment to this point," Michael K. Racke, MD, professor of neurology and neuroscience at Wexner Medical Center at The Ohio State University in Columbus, told Medscape Medical News.

Dr Racke is an investigator in the HALT-MS (High-dose Immunosuppression and Autologous Stem Cell Transplantation for Poor Prognosis Multiple Sclerosis) trial). http://www.halt-ms.org/ The 5-year results were presented at two sessions here at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting by Richard A. Nash, MD, from the Colorado Blood Cancer Institute, and James Bowen, MD, medical director of the Multiple Sclerosis Center at the Swedish Neuroscience Institute, Seattle, Washington.

Interim 3-year results were previously reported in JAMA Neurology in February 2015.

The 5-year follow-up shows that the regimen "was highly effective for inducing sustained remissions of highly active relapsing-remitting MS through the 5 years," said Dr Nash.

Brain lesions detected by MRI were reduced; brain volume stabilized; and disability, measured by the Expanded Disability Status Scale (EDSS), slightly improved by an average of half a point, said Dr Bowen.

Patients also were largely functionally stable according to several measures, including the Multiple Sclerosis Functional Composite assessment, he said.

Story Source: The above story is based on materials provided by MEDSCAPE
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News